Erlangen: For the companies that build heart valves, implantable pumps and diagnostic platforms, 2026 is the year the theory stops. Joint clinical assessment arrives for high-risk medical devices, and the first cohort of products has been lining up since spring.
The mechanism comes from the EU health technology assessment regulation, which already applies to new cancer medicines and advanced therapies. From this year it extends to class IIb and class III medical devices and class D in vitro diagnostics. One assessment team, drawn from national bodies, reviews the clinical evidence once on behalf of all 27 countries. National authorities then take that report and decide, as they always have, what to pay and whether to reimburse.
The Commission completed the legal scaffolding in October 2025 with an implementing regulation setting out the procedural rules for devices and diagnostics. In January the HTA Coordination Group published its report on emerging health technologies and identified up to fifteen devices potentially eligible for assessment during 2026. Selection decisions followed in the second quarter, the first assessments began around June, and the earliest reports are expected before the year closes.
Manufacturers describe the shift in blunt terms. Regulatory approval under the medical device rules asks whether a product is safe and performs as claimed. Joint clinical assessment asks a harder question, which is whether the device delivers better outcomes than whatever clinicians use now. That demands comparative evidence, and the device sector has historically generated far less of it than the pharmaceutical industry.
The dossier requirements make the gap visible. Developers must submit clinical evaluation data from the regulatory file, scientific opinions from expert panels, published and unpublished studies, and registry data where it exists. Registries are patchy across Europe and rarely designed to answer comparative effectiveness questions. Several companies have discovered that the trial that satisfied their notified body will not satisfy an assessment team.
Researchers who interviewed national HTA bodies during the run-up found a mirrored problem on the public side. Assessors flagged regulatory uncertainty, timing mismatches between the device approval pathway and the assessment calendar, and limited manufacturer readiness. The Commission publishes the procedural framework and ongoing assessments, but the volume of work falls on national agencies that are already stretched.
Smaller manufacturers carry the heaviest load. A large multinational can staff a market access team and commission a comparative study. A company with forty employees and a niche orthopaedic implant cannot, and the joint scientific consultation route that exists to advise developers early has limited capacity. If the evidence bar effectively screens out small European device firms, the regulation will have achieved harmonisation at the cost of the innovators it was meant to help.
The counterargument holds that fragmentation was worse. A manufacturer previously faced separate national reviews, each with its own comparator, evidence template and language, and the cumulative cost of satisfying them all dwarfed the cost of one rigorous assessment. Patients in smaller countries waited longest because their agencies reviewed last.
Which account proves right depends on what those first reports look like. Fifteen devices is a small sample, and the assessment teams know every national payer will read their output closely. The reports arriving this winter set the template that device companies will design trials around for the rest of the decade.
